Clinical & Financial Advantages of Genomic Sciences / Precision Medicine
Advances in Genomic Sciences have ushered in a new era of medicine, one based on DNA precision that is no longer bound to a one-size-fits-all approach. By employing a patient's genetic information, healthcare providers are now empowered to lessen the pain and costs of traditional trial and error methods when treating diseases and prescribing medications.
Privacy and Legal Considerations
The Genetic Information Nondiscrimination Act (GINA) makes it against the law for health insurers to request, require, or use genetic information to make decisions about eligibility for health insurance and health insurance premiums, contribution amounts, or coverage terms. The Act also prohibits employment discrimination on the basis of genetic information.
BASE10 uses third-party cloud platforms that meet Health Insurance Portability and Accountability Act (HIPAA) and HITRUST requirements for the storage and access of protected data. BASE10 follows strict guidelines for the protection of customer data and does not engage in the selling or marketing of genetic data.
BASE10 Genomics Programs
After the successful sequencing of the human genome in 2003, sequencing technologies have undergone dramatic advancements.
Two realized front runners in this field are:
The research and discovery of how individuals' genetic makeup interacts with their diet choices.
These findings can render important insights into chronic conditions which may be improved from modifications and/or exclusionary dietary practices.
The BASE10 Nutrigenomics program offers an unprecedented level of engagement with a team of accessible dietitians who guide participants through their DNA results and support them through their tailored-made nutrition and exercise curriculums. Our program defies the standard self-automated platforms by offering a solution that is specifically geared to reducing financial exposures by helping to:
- Reduce BMI and A1C by 1.0% in 6 months
- Target a 10% BMI reduction and or 10% reduction of A1C at 12 months
- Sustain a commitment of >5% BMI and or 1.0% A1C after the first year
The research and discovery of how individuals' genetic makeup affects their metabolism of and reaction to certain medications.
This analysis delivers preemptive insights that significantly support provider accuracy in determining the most suitable medication, its dosage, and how it may interact with other medications.
BASE10's Pharmacogenomics program digital platform was built from scratch to deliver precise, personalized action-oriented recommendations that effectively guide clinical decision-making to the most vulnerable.
- Curb adverse reactions from medications
- Reduce Loss Bed Revenue
- Improve medication compliance
- Limit unexpected costly consequences